

GW 4064

GW 4064 is a synthetic small molecule selective agonist of the orphan nuclear receptor FXR (EC50=15nM) developed by GlaxoSmithKline. Protects cells and organs against bile acid toxicity, and used to elucidate FXR's role in dyslipidemia, diabetes, obesity, and cancer. Has no activity against other nuclear receptors.

Materials Provided

Catalog Number:	92-1129
Quantity Supplied:	1 vial(s), 10 mg per vial

Description

DiscoverX control ligands have been functionally tested and validated for optimal use with all cell line targets and Assay Ready kits.

Product Information

Molecular Weight:	542.84 g/mol
Source:	Synthetic
Purity:	≥ 97%
Endotoxin Level:	N/A
Formulation:	N/A
Storage:	2-8°C Please avoid multiple freeze/thaw cycles.

Reagent Preparation

To avoid condensation, equilibrate the vial to ambient temperature before opening.

Stock Concentration:	5 mM
Reconstitution Volume:	3.684 mL
Reconstitution Solvent:	DMSO

Handling Instructions:

Desiccate

For Research Use Only

Ordering: +1.510.979.1415 option 4 or e-mail CustomerServiceDRX@eurofins.com
Technical support: +1.510.979.1415 option 5 or e-mail DRX_SupportUS@eurofinsUS.com
General product information: www.discoverx.com